PCLOF (PharmaCielo) Tariff Resilience Score: 6/10 (As of Jun. 25, 2026)


What is PharmaCielo Tariff Resilience Score?

PharmaCielo PCLOF -3.79% Tariff Resilience Score is 6 as of Jun. 25, 2026. The stock has 5 warning signs investors should review. Among 1,031 Drug Manufacturers companies, PharmaCielo ranks better than 90.98% on this metric.

PharmaCielo has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

PharmaCielo has Pharmaceuticals can face tariffs on raw materials and finished products. PharmaCielo's international operations expose it to some risk, but regulatory environments may offer exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes PharmaCielo might have Average Resilient.

PharmaCielo  (OTCPK:PCLOF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

PharmaCielo Tariff Resilience Score Related Terms

PCLOF vs ZTS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCielo Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where PharmaCielo's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 6 mean?
PharmaCielo (PCLOF) has a Tariff Resilience Score of 6 as of Jun. 25, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, PharmaCielo ranks #93 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 9%.
Is PharmaCielo's Tariff Resilience Score too high?
PharmaCielo's current Tariff Resilience Score is 6. Based on the distribution chart, PharmaCielo ranks #93 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does PharmaCielo's Tariff Resilience Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #93 out of 1031 companies for Tariff Resilience Score. This places PharmaCielo in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. PharmaCielo's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.05 — trading 50.5% below its estimated fair value. The current Tariff Resilience Score is 6. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current Tariff Resilience Score is 6 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.